A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2013
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 07 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 01 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.